Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348334 | 0.81 | APP (0.36) | KMT2AAPPLMNAAAK1MAPK1 | |
| SCHEMBL5215418 | 0.80 | ESR1 (0.42) | KMT2AAPPLMNAAAK1MAPK1 | |
| SCHEMBL14721160 | 0.80 | ESR1 (0.42) | KMT2AAPPLMNAAAK1MAPK1 | |
| SCHEMBL28880398 | 0.80 | HTT (0.43) | HTTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL15336461 | 0.80 | HTT (0.43) | HTTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL29824350 | 0.80 | HTT (0.43) | HTTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL29348329 | 0.77 | HTT (0.35) | HTTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL7746373 | 0.76 | GABRA1 (0.47) | KMT2AAPPLMNAAAK1 | |
| SCHEMBL16782680 | 0.75 | MEN1 (0.46) | KMT2AMEN1LMNACYP2C9CYP2C19 | |
| SCHEMBL5216247 | 0.75 | ITGA4 (0.40) | KMT2AAPPLMNAAAK1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |